Nonhematological adverse events grades 3 to 5 after BEAM/auto-SCT and FBC/allo-SCT
| . | Transplant recipients, n (%) . | |||
|---|---|---|---|---|
| . | BEAM/auto-SCT (n = 41)* . | FBC/allo-SCT (n = 26) . | ||
| Nausea | 2/40 | 5 | 2/26 | 8 |
| Vomiting | 1/40 | 2 | 1/26 | 4 |
| Diarrhea | 4/40 | 10 | 3/26 | 12 |
| Constipation | 0/41 | 0 | 0/26 | 0 |
| Mucositis/stomatitis | 13/41 | 32 | 6/26 | 23 |
| Cardiac arrhythmia | 1/40 | 2 | 1/25 | 4 |
| Cardiac general | 1/41 | 2 | 0/26 | 0 |
| Hemorrhage/bleeding | 2/41 | 5 | 1/26 | 4 |
| Renal/genitourinary | 0/41 | 0 | 4/26 | 15 |
| Neuropathy sensory | 0/41 | 0 | 0/26 | 0 |
| Mood alteration | 0/41 | 0 | 1/26 | 4 |
| Allergic reaction/hypersensitivity | 0/40 | 0 | 0/26 | 0 |
| Infections | 13/41 | 32 | 10/26 | 38 |
| Hepatotoxicity (other than VOD) | — | — | 1/26 | 4 |
| VOD | — | — | 0/26 | 0 |
| . | Transplant recipients, n (%) . | |||
|---|---|---|---|---|
| . | BEAM/auto-SCT (n = 41)* . | FBC/allo-SCT (n = 26) . | ||
| Nausea | 2/40 | 5 | 2/26 | 8 |
| Vomiting | 1/40 | 2 | 1/26 | 4 |
| Diarrhea | 4/40 | 10 | 3/26 | 12 |
| Constipation | 0/41 | 0 | 0/26 | 0 |
| Mucositis/stomatitis | 13/41 | 32 | 6/26 | 23 |
| Cardiac arrhythmia | 1/40 | 2 | 1/25 | 4 |
| Cardiac general | 1/41 | 2 | 0/26 | 0 |
| Hemorrhage/bleeding | 2/41 | 5 | 1/26 | 4 |
| Renal/genitourinary | 0/41 | 0 | 4/26 | 15 |
| Neuropathy sensory | 0/41 | 0 | 0/26 | 0 |
| Mood alteration | 0/41 | 0 | 1/26 | 4 |
| Allergic reaction/hypersensitivity | 0/40 | 0 | 0/26 | 0 |
| Infections | 13/41 | 32 | 10/26 | 38 |
| Hepatotoxicity (other than VOD) | — | — | 1/26 | 4 |
| VOD | — | — | 0/26 | 0 |
VOD, venous occlusive disease.
Seven patients randomized to allo-SCT are included.